Reading a Peptide Evidence Badge: A Semaglutide Trial Example
The STEP 1 semaglutide trial shows how to judge evidence for a defined adult weight-loss outcome while keeping other claims and safety questions separate.
A claim narrow enough to assess
What does the evidence say about weight loss in adults with obesity, or overweight with a weight-related condition, who do not have diabetes? That is more answerable than “does semaglutide work?” The STEP 1 randomized trial enrolled 1,961 adults in that population. Participants received subcutaneous semaglutide or placebo, both alongside a lifestyle intervention, and were followed for 68 weeks. This is an example of reading evidence, not treatment guidance.
What the sources establish
| Question | What the source shows | Boundary |
|---|---|---|
| Did the trial measure a human outcome directly? | STEP 1 randomized adults and measured change in body weight. Mean change at 68 weeks was -14.9% with semaglutide and -2.4% with placebo. PMID: 33567185 | The result is for the studied population, comparison, outcome, and time frame. It does not measure every use of semaglutide. |
| Is this an approved use? | The FDA prescribing information includes weight reduction and long-term maintenance indications for specified populations and summarizes additional clinical studies. | Approval is a separate regulatory decision; it is not a grade for all possible benefits or harms. |
| Are safety questions closed? | The same FDA label describes warnings, contraindications, and adverse reactions. | A weight-loss result does not establish safety for every person or settle every rare or long-term risk. |
What this example says about the badge
The semaglutide dossier shows a High Evidence badge for the compound. For adult weight-loss efficacy in the population studied, STEP 1 provides direct randomized human evidence, and the FDA label summarizes a broader clinical program. Those sources help explain why this particular claim has substantial support. The compound badge does not assign a separate high grade to that outcome or to every other claim about semaglutide. It is not a formal GRADE rating. A formal GRADE assessment examines the full body of evidence for a defined outcome, including risk of bias, inconsistency, indirectness, imprecision, and publication bias. PMID: 21208779
Do not read the compound’s High badge as a high-certainty conclusion for a different indication, population, or safety outcome. For those questions, start again with the claim and its relevant evidence. GRADE’s original framework also separates confidence in evidence from a recommendation to use a treatment.
See the peptide evidence levels reference for the four labels and a checklist for reading other studies. This article is educational and does not provide medical advice.
Sources & Citations
- 1
- 2
- 3
- 4
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.